Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Deciphera Pharmaceuticals Inc
(NQ:
DCPH
)
14.62
+0.45 (+3.14%)
Streaming Delayed Price
Updated: 1:11 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Deciphera Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 09, 2022
Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares...
Via
Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
February 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
February 08, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For February 8, 2022
February 08, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
February 02, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022
February 01, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
January 24, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
January 23, 2022
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that...
Via
Talk Markets
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
January 23, 2022
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...
Via
Benzinga
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
January 10, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
December 21, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera: Why There Won’t Be a Quick Recovery
December 09, 2021
It will take awhile for DCPH stock to recover after major clinical setback
Via
InvestorPlace
691 Stocks Are Down Over 50% This Year
December 05, 2021
It may be hard to believe because the stock market has been in such an uptrend this year, but there are some interesting statistics for stock performance year-to-date.
Via
Talk Markets
Why Deciphera Pharmaceuticals Shot 12% Higher Today
November 30, 2021
The company announced a comprehensive restructuring program.
Via
The Motley Fool
Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard
November 30, 2021
Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials.
Via
InvestorPlace
Deciphera Pharma Stock Rises After Announcing Corporate Restructuring
November 30, 2021
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) will undergo a corporate restructuring to eliminate 35% of its workforce and end a Phase 1/2 program for solid tumors...
Via
Benzinga
Don’t Bet on a Deciphera Stock Comeback
November 30, 2021
Investors weren't wrong in dumping DCPH stock after terrible top-line results for the biotech company's flagship candidate. Avoid for now.
Via
InvestorPlace
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
November 30, 2021
From
Deciphera Pharmaceuticals
Via
Business Wire
Deciphera's Qinlock Approved In Europe For Gastric Cancer
November 22, 2021
The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ: DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal...
Via
Benzinga
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
November 22, 2021
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals
November 16, 2021
Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip.
Via
InvestorPlace
Topics
Earnings
Exposures
Financial
What 6 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
November 08, 2021
Analysts have provided the following ratings for Deciphera Pharmaceuticals (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
November 08, 2021
Upgrades For Nektar Therapeutics (NASDAQ:
Via
Benzinga
10 Biggest Price Target Changes For Monday
November 08, 2021
Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ:
Via
Benzinga
Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher
November 05, 2021
Toward the end of trading Friday, the Dow traded up 0.57% to 36,331.86 while the NASDAQ rose 0.20% to 15,972.41. The S&P also rose, gaining 0.40% to 4,698.70. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plunging 70%?
November 05, 2021
Today, investors in Deciphera Pharmaceuticals and DCPH stock have seen tremendous selling pressure take this stock to all-time lows.
Via
InvestorPlace
92 Biggest Movers From Friday
November 08, 2021
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.